Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Intra-Cellular Therapies Inc Market Cap
Based on ratings from 16 stock analysts, the Intra-Cellular Therapies Inc stock price is expected to increase by 20.48% in 12 months. This is calculated by using the average 12-month stock price forecast for Intra-Cellular Therapies Inc. The lowest target is $79 and the highest is $135. Please note analyst price targets are not guaranteed and could be missed completely.
ITCI is a stock in Healthcare which has been forecasted to be worth $101.86667 as an average. On the higher end, the forecast price is $135 USD by from and on the lower end ITCI is forecasted to be $79 by Brian Abrahams from RBC Capital.
These are the latest 20 analyst ratings of ITCI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jessica Fye JP Morgan | Overweight | $89 | Maintains | Nov 4, 2024 |
| Ami Fadia Needham | Buy | $100 | Reiterates | Oct 31, 2024 |
| Ami Fadia Needham | Buy | $100 | Reiterates | Oct 30, 2024 |
| Jeffrey Hung Morgan Stanley | Overweight | $95 | Maintains | Oct 11, 2024 |
| Brian Abrahams RBC Capital | Outperform | $108 | Maintains | Oct 4, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $130 | Reiterates | Sep 20, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $130 | Reiterates | Sep 16, 2024 |
| Charles Duncan Piper Sandler | Overweight | $92 | Upgrade | Sep 6, 2024 |
| Jessica Fye JP Morgan | Overweight | $81 | Maintains | Aug 21, 2024 |
| Corinne Jenkins Goldman Sachs | Neutral | $74 | Maintains | Aug 8, 2024 |
| Ashwani Verma UBS | Neutral | $79 | Maintains | Aug 8, 2024 |
| Ami Fadia Needham | Buy | $100 | Reiterates | Aug 8, 2024 |
| Brian Abrahams RBC Capital | Outperform | $106 | Maintains | Aug 8, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $130 | Maintains | Aug 8, 2024 |
| Ami Fadia Needham | Buy | $100 | Reiterates | Aug 7, 2024 |
| Ami Fadia Needham | Buy | $100 | Maintains | Jul 22, 2024 |
| Brian Abrahams RBC Capital | Outperform | $103 | Reiterates | Jun 25, 2024 |
| Ashwani Verma UBS | Neutral | $83 | Downgrade | Jun 25, 2024 |
| Graig Suvannavejh Mizuho | Buy | $100 | Maintains | Jun 21, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $113 | Maintains | Jun 20, 2024 |
When did it IPO
2014
Staff Count
610
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Dr. Sharon Mates Ph.D.
Market Cap
$8.96B
In 2023, ITCI generated $462.2M in revenue, which was a increase of 85.51% from the previous year. This can be seen as a signal that ITCI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Intra-Cellular Therapies, Inc. submitted a supplemental New Drug Application to the FDA for CAPLYTA (lumateperone) to treat Major Depressive Disorder as an adjunctive therapy.
Why It Matters - The FDA submission for CAPLYTA could lead to expanded market opportunities, potentially boosting revenue and stock performance for Intra-Cellular Therapies, impacting investor sentiment positively.
Wed, 04 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Intra-Cellular has submitted a supplemental New Drug Application (sNDA) to the FDA for Caplyta, seeking to expand its use for treating major depressive disorder (MDD) in adults as an adjunct to antidepressants.
Why It Matters - Intra-Cellular's sNDA for Caplyta could expand its market potential, potentially boosting revenue and stock value if approved, impacting investor sentiment and market positioning.
Fri, 29 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Intra-Cellular (ITCI) recently reported earnings 30 days ago. Investors should monitor upcoming developments for insights on potential stock performance.
Why It Matters - ITCI's recent earnings report can influence stock price and investor sentiment. Upcoming developments or guidance can indicate growth potential or risks, impacting investment decisions.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) CEO Sharon Mates will present at three upcoming investor conferences, focusing on CNS disorder therapeutics.
Why It Matters - The announcement of CEO Sharon Mates presenting at investor conferences signals potential growth and interest in Intra-Cellular Therapies, which could influence stock performance and investor sentiment.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Reuters
Summary - Intra-Cellular Therapies announced that its schizophrenia relapse prevention drug successfully met the primary endpoint in a late-stage clinical trial.
Why It Matters - Successful trial results for Intra-Cellular Therapies' schizophrenia drug could lead to regulatory approval, increased sales, and higher stock value, impacting investor sentiment positively.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Two pivotal studies (501 and 502) have presented results on lumateperone as an adjunctive therapy to antidepressants for treating major depressive disorder (MDD).
Why It Matters - Positive results from Studies 501 and 502 could enhance lumateperone's market potential, impacting the stock value of the company and influencing investor sentiment in the biotech sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
